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CRC; patients are now expected to survive longer and have the potential to expe-
rience various side effects related to chemotherapy. Knowing how patients value
the outcomes and preferences of treatment options for CRC is important to oncol-
ogists and policy makers in planning and introducing treatment interventions.
METHODS:Qualitative interviewswith 27 CRC patientswere used to identify seven
treatment attributes and their levels with regard to chemotherapy for CRC, for
inclusion in a discrete choice experiment (DCE) survey. These attributes were: life
expectancy, fatigue, diarrhoea, oral symptoms, hair loss, pain, and nausea and
vomiting. The survey was completed by 150 CRC patients to assess their prefer-
ences for the treatment of CRC. A conditional logit model was used to analyse the
data using STATA v9.0. RESULTS: The results of the DCE survey showed that, with
the exception of oral symptoms, all other attributes were found to be important
factors when it came to treatment decisions made by participants. The results
confirmed the prior hypothesis about the directions of attributes. For example, life
expectancy had a positive coefficient value, which indicated that the greater the
life expectancy, the more likely a participant would be to prefer that treatment. In
contrast, the negative values for pain, diarrhoea, fatigue, nausea and vomiting, and
hair loss indicate that participantswould not prefer a treatment that produce these
toxicities. Patients preferred to trade-off life expectancy for the reduction in the
likelihood of specific side effects. CONCLUSIONS: The results indicate the types of
risks and benefits that are important to patients with treatments for CRC. The
findings are likely to assist health care professionals in prioritising issues that need
to be discussed during treatment consultations.
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OBJECTIVES: This research study aimed to investigate the perception of cancer
patients towards the use of Traditional & Complementary Medicines (T&CM) for
cancer treatment. METHODS: Qualitative methodology was adapted to collect in-
depth information from consented cancer patients who were recruited from the
oncology wards at Penang General Hospital from May 2010 to August 2010. After
obtaining institutional ethical approval, patients with different types of cancer and
stages from the three major ethnic groups in Malaysia namely Malay, Chinese and
Indians were approached. Twenty semi-structured interviews were conducted af-
ter obtaining informed consent. All interviews were audiotaped, transcribed ver-
batim and translated into English for thematic content analysis. RESULTS: A total
of 3 themes were identified from the interview analysis: 1) positive attitude to-
wards spiritual ways of healing for cancer treatment, 2) concerns about the safety
and efficacy of T&CM for cancer treatment; and 3) concerns towards the legitimacy
of the claims made by traditional practitioners. Patients were willing to try non-
invasive treatments such as prayers, spiritual and faith healing therapies for can-
cer treatment. Lack of a fixed dosing system, unknown side effects and substan-
dard methods of preparation were other reported reasons for rejecting T&CM use.
The respondents showed a great concern towards the authenticity of claimsmade
by traditional practitioners and the majority demanded that true and fair claims
should be made by traditional practitioners in order to help patients in making
decisions regarding cancer therapy. CONCLUSIONS: The respondents in this study
did not appear to have attitudes regarding TCM that could lead to treatment delays
but thismay be due to the samplingmethod. Future studies are needed to evaluate
perceptions among thosewhohave defaulted treatment at any stage of cancer. The
current study has contributed to a greater understanding of the use of T&CM
among cancer patients that are not defaulting treatment.
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OBJECTIVES: New treatment improves efficacy and often has toxicities. The qual-
ity-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis in-
corporates survival, toxicities and quality of life into a single metric providing an
integrated measure of clinical benefit. Objective of this study was to use Q-TWiST
analysis comparing quality-adjusted survival between patients with chemo-re-
fractory wild-type KRAS metastatic colorectal cancer (mCRC) receiving panitu-
mumab  best supportive care (BSC) versus BSC alone. Because the trial design
allowed patients on BSc arm to receive panitumumab after disease progression,
whichmay have confounded overall survival (OS), the focus of this analysis was on
progression-free survival (PFS).METHODS: The time spent in the toxicity (grade 3
or 4 adverse events; TOX), time without symptoms of disease or toxicity (TWiST),
and relapse (after disease progression; REL) states were estimated, and adjusted
using utility weights derived from patient-reported EQ-5D measures. Quality-ad-
justed PFS was when the utility for REL was zero in the Q-TWiST analysis. Sensi-
tivity analyses were performed in which utility weights (varying from 0 to 1) were
applied to TOX and REL health states. RESULTS: The trial included 463 patients,
KRAS status ascertained in 427 (92%) of patients. Of these, 243 (57%) having wild-
type KRAS tumours (124 panitumumab BSC, 119 BSC alone) were included in the
analysis. Statistically significant difference between groups in quality-adjusted PFS
favoured panitumumab  BSC (12.3 weeks versus 5.8 weeks, respectively,
p0.0001). The difference continued to favour panitumumab  BSC for all hypo-
thetical utility weights applied to the TOX health state in sensitivity analyses.
Although OS was confounded by 76% of patients in the BSC alone arm receiving
panitumumab after disease progression, the difference in quality-adjusted OS was
also statistically significant and favoured panitumumab BSC. CONCLUSIONS: In
patients with chemo-refractory wild-type KRAS mCRC, panitumumab  BSC sig-
nificant improved quality-adjusted survival compared with BSC alone.
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OBJECTIVES: Our objective was to understand how oncologists view patient-re-
ported outcomes (PROs) and whether PRO data influences their clinical decision
making. METHODS: Twenty oncologists participated in 1 of 4 semi-structured fo-
cus groups (5 per group). Topics for discussion included: relative value of PROs
compared to other efficacy outcomes, impact of PROs on clinical decision making,
and interpretation of PRO data. Transcripts were analyzed using Atlas.ti software.
RESULTS: The oncologists represented a diverse sample in terms of gender (55%
male), years in practice (4-25), practice type/size, and tumor specialty. Most oncol-
ogists had no experience with PROs, but were able to identify several concepts
appropriate for PRO assessment (e.g., symptoms and functioning). All oncologists
agreed that when treating curable disease, clinical efficacy (overall survival, pro-
gression free survival) and toxicity were the main drivers of clinical decision mak-
ing. In the non-curative setting, all agreed that PRO data, particularly health-re-
lated quality of life data becomes paramount as a driver of treatment decision
making. Some oncologists felt that patient-reported symptoms were on a par with
toxicology, and saw a benefit to supplementing toxicity data with PRO data. All
agreed that patients were the best source of data regarding symptoms and that
many symptomswere consistent across tumor types. Concern over the subjectivity
and interpretability of PROs, however, was expressed and most oncologists stated
a preference for common toxicity criteria and performance status measures (e.g.,
Karnofsky). Most oncologists agreed that clear and concise reports of PRO datawith
clear explanations of the scale used and interpretability of change would increase
their likelihood of reviewing PRO data. CONCLUSIONS: Oncologists prioritize clin-
ical efficacy endpoints in their treatment decision making; however, in the non-
curative setting PRO data becomesmore influential. Improving the interpretability
of PROmeasures could increase the use of PRO data in treatment decisionmaking.
PCN88
ATTITUDES OF YOUNG WOMEN ON HUMAN PAPILLOMA VIRUS VACCINATION
Chopra P, Shah J, Fase B, Sansgiry S
University of Houston, Houston, TX, USA
OBJECTIVES: This study evaluated knowledge and attitude towards human papil-
loma virus (HPV) vaccination among women ages 18-24 years and examined pre-
dictors of attitude towards HPV vaccination. METHODS: A cross-sectional, self-
administered questionnaire was delivered to a convenience sample of female
University students in 2009. Questions on knowledge (9 items) and attitude (2
items) were measured using a 5-point Likert scale. The instrument also included
questions on demographics, HPV vaccination status, source of HPV-related infor-
mation, and healthcare professional’s recommendation. For the purpose of mod-
eling, knowledge (yes/no) and attitude (positive/negative) was reduced to a binary
variable. Data was coded and analyzed using SAS v9.2, by conducting descriptive
analyses, chi-square tests and logistic regression. RESULTS: A total of 136 subjects
completed the survey with a response rate of 46.5%. The mean age of the sample
was 20.67(1.78) years with the majority being unmarried (88.97%) and insured
(72.06%). HPV vaccination rate was 11%. Themean summary knowledge score was
4.4 (3.0) with a reliability coefficient of 0.7. Themean summary attitude scorewas
2.7 (1.2) with a reliability coefficient of 0.8. In the logistic regressionmodel, health
care professional’s recommendation to administer HPV vaccine was a significant
predictor of positive attitude towards the vaccine (OR2.886, 95% CI1.186-7.020,
p0.05) after controlling for race, education, age, knowledge, and vaccination
status. CONCLUSIONS: A healthcare professional’s recommendation to consider
the HPV vaccine was a significant predictor of attitude towards the vaccine. Sub-
optimal knowledge and negative attitude towards HPV vaccination underscore the
need for active education and accurate dissemination of information to women
regarding HPV vaccination.
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OBJECTIVES: Inform clinical trial designs with regards to Health Technology As-
sessment (HTA) agencies’ preferences regarding Quality of Life (QoL) measures for
prostate cancer. METHODS: We searched the Centre for Reviews and Dissemina-
tion database and HTA Watch® for any publication by an HTA agency on prostate
cancer and QoL using the search string “prostate cancer ANDQoL OR quality of life.
RESULTS:We identified 19 HTAs. Four HTAs evaluated drug treatments, 14 evalu-
ated procedures and one evaluated screening. The year of publication ranged from
1996 to 2007. UK agencies published eight of the HTAs, including the four evaluat-
ing drugs, a Norwegian agency published three, and agencies in France, Spain and
the US each published two, with the remaining HTA published by a German
agency. The results of the HTA review demonstrate a consensus regarding a lack of
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